Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyViva Health bevacizumab Coverage & Prior Auth | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentViva HealthPolicy N/A

    Bevacizumab (and listed biosimilars) — Intravenous oncology coverage and prior authorization criteria

    Customize your policy alerts

    Sign up for all Viva Health policy alerts

    Know when Viva Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage and prior authorization criteria for bevacizumab and listed biosimilars for oncology indications for Viva Health members; defines authorization length, dosing unit limits, and indication-specific clinical criteria.

    Policy Summary
    PayerViva Health
    PolicyBevacizumab (and listed biosimilars) — IV oncology coverage & prior authorization criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewDec 2, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization showing patient meets universal and indication-specific criteria and documentation of prior lines of therapy and required diagnosis code.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsstandard initial prior authorization validity
    12 weeksadult CNS initial authorization
    18+minimum patient age
    Yesrenewal requires disease response
    170-360max HCPCS unit ranges

    Coverage Criteria and Indication-Specific Rules

    inv-01: Universal Initial Criteria

    Initial approval requires ALL of the following universal criteria:

    Universal: Patient must have a contraindication, intolerance, or failure to Alymsys AND Mvasi prior to consideration of another bevacizumab product; patient is at least 18 years of age unless otherwise specified; no recent history of hemoptysis (≥2.5 mL blood in sputum); and no surgical procedure within the preceding 28 days and no unhealed surgical wound.

    inv-02: Ampullary Adenocarcinoma

    Ampullary Adenocarcinoma — Covered when ALL of the following are met:

    Ampullary Adenocarcinoma: Used in combination with a fluoropyrimidine-based regimen (e.g., 5-FU or capecitabine) for intestinal-type disease; and either used as first-line therapy for metastatic disease or used for disease progression.

    inv-03: Adult CNS Cancers (symptom management and other CNS uses)

    Policy Summary
    PayerViva Health
    PolicyBevacizumab (and listed biosimilars) — IV oncology coverage & prior authorization criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewDec 2, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization showing patient meets universal and indication-specific criteria and documentation of prior lines of therapy and required diagnosis code.
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific RulesBilling, Code Lists, and Unit LimitsAuthorization, Documentation, and Denial Risk GuidanceLine of Therapy and Sequencing RulesBiomarker and Molecular Testing RequirementsExamples of Covered Combination RegimensDefinitions and Clinical TermsBackground and Clinical Context

    Adult CNS Cancers — Covered when ANY of the following indication-specific conditions are met in addition to universal criteria:

    CNS symptomatic indications: Used as single-agent for symptomatic mass effect, radiation necrosis, or brain edema in patients with listed CNS tumor types (examples: circumscribed glioma, primary CNS lymphoma, meningiomas, brain or spine metastases, primary spinal cord tumors, medulloblastoma, glioblastoma/gliosarcoma, H3‑mutated high‑grade glioma/HGAP/PXA WHO grade 3, IDH‑mutant astrocytoma WHO grade 2–4, IDH‑mutant 1p19q‑codeleted oligodendroglioma WHO grade 2–3, intracranial or spinal ependymoma excluding subependymoma).
    CNS recurrent/progressive: Used for recurrent or progressive disease for specified tumor types (e.g., IDH‑mutant 1p19q‑codeleted oligodendroglioma WHO grade 3; glioblastoma/gliosarcoma; H3‑mutated high‑grade glioma/HGAP/PXA WHO grade 3; IDH‑mutant astrocytoma WHO grade 3–4) as single agent or in combination with carmustine, lomustine, or temozolomide; and may be considered when patient has failed prior bevacizumab monotherapy where specified.
    Other CNS uses: Used as single agent for intracranial or spinal ependymoma after prior radiation; used in combination with temozolomide and irinotecan for recurrent medulloblastoma; used as single agent for surgically inaccessible meningiomas when radiation is not possible; and used as single agent for NF2 vestibular schwannomas with hearing loss.

    inv-04: Cervical Cancer

    Cervical Cancer — Covered when ALL of the following are met:

    Cervical Cancer: Patient has persistent, recurrent, or metastatic disease of adenocarcinoma, adenosquamous, or squamous histology; used in combination with paclitaxel and either cisplatin, carboplatin, or topotecan; or used in combination with pembrolizumab plus paclitaxel and either cisplatin or carboplatin when tumor PDL1 (CPS) ≥1 by an FDA‑approved or CLIA‑compliant test; or used in combination with atezolizumab plus paclitaxel and either cisplatin or carboplatin; or used as single‑agent subsequent therapy. Small cell neuroendocrine carcinoma (NECC) regimens specified (paclitaxel + topotecan) apply for first‑line or subsequent therapy. Bevacizumab and certain immunotherapy regimens may be continued as maintenance as noted.PDL1 (CPS) >=1

    PDL1 testing must be FDA‑approved or CLIA‑compliant.

    inv-05: Colorectal Cancer

    Colorectal Cancer (CRC) — Covered when ALL of the following are met:

    CRC: Will not be used as part of adjuvant treatment; used in combination with a fluoropyrimidine‑based regimen as first‑line or subsequent therapy for metastatic, unresectable, or advanced disease; or used in combination with irinotecan as initial treatment for unresectable metastatic disease (with prior FOLFOX/CapeOX within 12 months where specified); or used in combination with irinotecan‑based therapy or with trifluridine/tipiracil as subsequent therapy after progression through available regimens; or used as primary treatment for specified rectal staging when resection is contraindicated following neoadjuvant/definitive therapy.

    Refer to NCCN guidelines; universal MMR/MSI testing recommended and dMMR/MSI‑H or ultrahypermutated (TMB>50) tumors should be treated with checkpoint inhibitors when appropriate.

    inv-06: Appendiceal Neoplasms and Cancers

    Appendiceal Neoplasms and Cancers — Covered when ALL of the following are met:

    Appendiceal: Used as neoadjuvant therapy or for biopsy‑proven recurrence of high‑risk disease in combination with a fluoropyrimidine‑based regimen; used for metastatic peritoneal‑only disease or as initial therapy for recurrent/metastatic peritoneal‑only or extraperitoneal disease in combination with a fluoropyrimidine‑based regimen; or used as subsequent therapy in combination with a fluoropyrimidine‑ or irinotecan‑based regimen or with trifluridine/tipiracil after progression through available regimens.

    Refer to NCCN guidance.

    inv-07: Endometrial Carcinoma

    Endometrial Carcinoma — Covered when ALL of the following are met:

    Endometrial: Used for recurrent disease; will not be used for locoregional recurrence in patients without prior radiation to the site of recurrence or after surgical exploration confined to vagina/paravaginal soft tissue; and may be used as single‑agent subsequent therapy after progression on cytotoxic chemotherapy, or in combination with carboplatin and paclitaxel and continued as single‑agent maintenance, or as primary/adjuvant therapy for stage III–IV disease in combination with carboplatin and paclitaxel with continued single‑agent maintenance.

    inv-08: Hepatocellular Carcinoma

    Hepatocellular Carcinoma (HCC) — Covered when ALL of the following are met:

    HCC: Used in combination with atezolizumab as first‑line therapy for unresectable or metastatic disease, or used as subsequent therapy for progression on or after systemic therapy; and patient has not received prior treatment with bevacizumab or a checkpoint inhibitor.

    inv-09: Peritoneal Mesothelioma

    Peritoneal Mesothelioma — Covered when ALL of the following are met:

    Peritoneal Mesothelioma: Used as adjuvant therapy following CRS+HIPEC in combination with pemetrexed and either cisplatin or carboplatin for patients with surgical/pathologic high‑risk features; or used as first‑line or subsequent therapy in combination with pemetrexed and platinum under specified conditions (e.g., medically inoperable disease, inability to achieve complete cytoreduction, presence of high‑risk features, progression after CRS+HIPEC); may be used with atezolizumab if no prior checkpoint inhibitor therapy.

    High‑risk features include Ki‑67 >9%, nodal metastasis, thrombocytosis, PS=2, PCI>17, cc>1, biphasic/sarcomatoid histology, or bicavitary disease.

    inv-10: Pleural Mesothelioma

    Pleural Mesothelioma — Covered when ALL of the following are met:

    Pleural Mesothelioma: Used in combination with pemetrexed and either cisplatin or carboplatin as induction prior to surgical exploration for clinical stage I epithelioid histology, or used as first‑line or subsequent therapy; may be rechallenged after prior pemetrexed‑based first‑line response.

    inv-11: Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

    Non‑Squamous Non‑Small Cell Lung Cancer (NSCLC) — Covered when specified biomarker and combination therapy conditions are met:

    NSCLC first‑line: Used for recurrent, advanced, or metastatic disease as first‑line therapy in combination regimens depending on biomarker status (examples: with erlotinib for EGFR exon 19 deletion or L858R; with carboplatin and paclitaxel; or with atezolizumab, carboplatin, and paclitaxel). Actionable biomarker testing (EGFR, KRAS, ALK, ROS1, BRAF, NTRK, MET, RET, NRG1, ERBB2) is recommended to guide selection.
    NSCLC subsequent/maintenance: Used as subsequent therapy in combination with atezolizumab, carboplatin, and paclitaxel (excluding patients with prior PD‑1/PD‑L1 inhibitor therapy); or used as continuation maintenance after response or as single‑agent maintenance if bevacizumab was included in first‑line; includes biomarker‑dependent pathways and contraindication notes for PD‑1/PD‑L1 inhibitors.

    PD‑1/PD‑L1 contraindications may include active autoimmune disease or immunosuppression.

    inv-12: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

    Ovarian, Fallopian Tube, and Primary Peritoneal Cancer — Covered when specified histology, platinum‑sensitivity, biomarker, and combination regimen criteria are met:

    Ovarian general: Coverage varies by histology and platinum sensitivity: uses include single‑agent for relapsed sex cord‑stromal tumors; combinations for platinum‑resistant or platinum‑sensitive disease; maintenance uses and combinations with PARP inhibitors contingent on BRCA1/2 and homologous recombination (HR) status and histology; neoadjuvant, adjuvant, post‑IDS, and continued treatment contexts specified with surgical candidacy criteria.

    BRCA1/2 and HR status considerations apply; refer to histology‑specific subclauses.

    Gynecologic combinations and maintenance: Used in combination with paclitaxel and carboplatin for rising CA‑125 or clinical relapse in patients with no prior chemotherapy for specified histologies; used as maintenance therapy following primary therapy including bevacizumab; used as single agent in BRCA1/2 wild‑type or unknown patients with certain histologies; used in combination with olaparib or niraparib as indicated.
    Surgical timing and histology clauses: Neoadjuvant and IDS settings: used following IDS for response or stable disease to neoadjuvant therapy (endometrioid and serous only) when patient is poor surgical candidate or unlikely to achieve optimal cytoreduction; adjuvant use with oxaliplatin/docetaxel excludes grade 1 endometrioid and low‑grade serous carcinoma; detailed histology limits and BRCA/HR requirements apply per subclauses.

    inv-13: Ovarian/Fallopian Tube/Primary Peritoneal Cancer

    Ovarian/Fallopian Tube/Primary Peritoneal Cancer — covered when specific histology, setting, and biomarker criteria are met:

    Overall allowed contexts: Used in combination with paclitaxel and carboplatin for rising CA‑125 or clinical relapse or recurrence in patients with no prior chemotherapy for specified histologies; used as maintenance therapy; used as single agent following recurrence therapy with chemotherapy plus bevacizumab for platinum‑sensitive disease; continued treatment following neoadjuvant therapy for endometrioid and serous histology; neoadjuvant, adjuvant, and post‑IDS uses with histology and surgical candidacy criteria specified.

    See histology and biomarker subclauses.

    Histology/biomarker clauses: Coverage specifies histology‑limited uses (grade 2/3 endometrioid, high‑grade serous, mucinous, clear cell, carcinosarcoma, low‑grade serous in limited contexts) and requires BRCA1/2 wild‑type or unknown with HR deficiency or germline/somatic BRCA1/2 mutation for certain single‑agent or combination uses.
    Surgical timing and candidacy: Neoadjuvant and interval debulking surgery settings: used following IDS for response or stable disease to neoadjuvant therapy (endometrioid and serous only) when patient is a poor surgical candidate or unlikely to achieve optimal cytoreduction; adjuvant use in pathologic stage II–IV excludes grade 1 endometrioid and low‑grade serous carcinomas for certain regimens.

    inv-14: Pediatric Central Nervous System (CNS) Cancers

    Pediatric CNS Cancers — covered for specific tumor types, ages, and regimens:

    Pediatric CNS uses: Recurrent or progressive diffuse high‑grade glioma (≤21 years) as single‑agent palliative; medulloblastoma (age 3–21) as part of TEMR or MEMMAT regimens; optic pathway glioma (<18 years) as subsequent treatment to preserve vision (single agent or with standard therapies); NF2 vestibular schwannomas (≥6 years) with hearing loss in at least one ear; continuation after progression on bevacizumab to preserve vision/hearing as specified.

    Age and histology restrictions apply.

    inv-15: Renal Cell Carcinoma (RCC)

    Renal Cell Carcinoma (RCC) — Covered when indication‑specific criteria are met:

    RCC contexts: Used in combination with interferon alfa for metastatic disease; or in relapsed or stage IV non‑clear cell histology in combination with everolimus or with erlotinib for advanced papillary disease including HLRCC‑associated RCC. When used first‑line for stage IV disease, disease must be M1 or unresectable T4, M0.

    inv-16: Respiratory Papillomatosis

    Respiratory Papillomatosis — Covered when indication‑specific criteria are met:

    Adjunct use: Used as an adjunct to endobronchial therapy (e.g., surgical excision, debridement) for recurrent disease.

    inv-17: Small Bowel Adenocarcinoma

    Small Bowel Adenocarcinoma — Covered when ALL of the following are met:

    Small Bowel Adenocarcinoma: Patient has advanced or metastatic disease and bevacizumab is used in combination with a fluoropyrimidine‑based regimen; used as initial therapy if pMMR/MSS disease or as subsequent therapy if not previously given.

    inv-18: Soft Tissue Sarcoma (STS)

    Soft Tissue Sarcoma (STS) — Covered when ALL of the following are met:

    STS uses: Used as a single agent for angiosarcoma; or used in combination with temozolomide for solitary fibrous tumor.

    inv-19: Vaginal Cancer

    Vaginal Cancer — Covered when ALL of the following are met:

    Vaginal cancer contexts: Patient has recurrent or metastatic disease and bevacizumab is used in combination with paclitaxel and either cisplatin, carboplatin, or topotecan as first‑line or subsequent therapy; or used in combination with pembrolizumab, paclitaxel, and either cisplatin or carboplatin when tumor PDL1 (CPS) ≥1 by an FDA‑approved or CLIA‑compliant test for first‑line or subsequent therapy; or used as single‑agent subsequent therapy.PDL1 (CPS) >=1

    PDL1 testing must be FDA‑approved or CLIA‑compliant.

    inv-20: Vulvar Cancer

    Vulvar Cancer — Covered when ALL of the following are met:

    Vulvar cancer contexts: Patient has advanced, recurrent, or metastatic disease; used as first‑line or subsequent therapy (if not previously used) in combination with paclitaxel and either cisplatin or carboplatin, or in combination with pembrolizumab plus paclitaxel and cisplatin/carboplatin; bevacizumab (and pembrolizumab where used) may be continued as maintenance as noted.

    Will not be used as part of adjuvant treatment for colorectal cancer. For metastatic, unresectable, or advanced colorectal disease, bevacizumab is covered only in combination with a fluoropyrimidine-based regimen or with irinotecan-based therapy as specified in the colorectal coverage criteria and per NCCN guidance; adjuvant (post‑resection) use is excluded.

    Will not be used for locoregional recurrence in endometrial carcinoma without prior radiation to the site of recurrence or after surgical exploration confined to the vagina or paravaginal soft tissue. Coverage for endometrial carcinoma is limited to recurrent disease and to the specific combination or single‑agent contexts described in the policy (for example, combination with carboplatin/paclitaxel with continuation as single‑agent maintenance, or single‑agent subsequent therapy after progression on cytotoxic chemotherapy).

    Certain regimens explicitly exclude use in grade 1 endometrioid carcinoma and low grade serous carcinoma. Specifically, oxaliplatin/docetaxel combinations and adjuvant oxaliplatin/docetaxel are not allowed for these lower‑grade histologies as noted in the ovarian/fallopian tube/primary peritoneal cancer criteria and associated surgical/adjuvant clauses.

    IndicationCovered bevacizumab combination/regimenCoverage status
    Colorectal cancer (CRC)
    Bevacizumab in combination with fluoropyrimidine-based regimens (e.g., FOLFOX, CapeOX, FOLFIRI) for metastatic/unresectable CRC; may be continued after progression per clinical context
    IndicationCovered bevacizumab combination/regimenCoverage status
    Ovarian, fallopian tube, primary peritoneal cancer (gynecologic cancers)
    Bevacizumab combined with paclitaxel + carboplatin; carboplatin + paclitaxel or docetaxel; oxaliplatin + docetaxel (with histology exclusions); used as maintenance or single agent in biomarker-specified contexts; may be combined with PARP inhibitors (olaparib or niraparib) when specified by BRCA/HR status
    IndicationCovered bevacizumab combination/regimenCoverage status
    Pediatric central nervous system (CNS) tumors
    Single-agent bevacizumab or in combination as part of TEMR (temozolomide, irinotecan, bevacizumab) or MEMMAT (thalidomide, celecoxib, fenofibrate, etoposide, cyclophosphamide, bevacizumab) regimens; also combined with standard therapies (e.g., irinotecan, carboplatin, vinblastine) depending on tumor type and age-specific criteria
    IndicationCovered bevacizumab combination/regimenCoverage status
    Small bowel adenocarcinoma
    Bevacizumab combined with a fluoropyrimidine-based regimen (e.g., 5-FU or capecitabine) for advanced/metastatic disease; used as initial therapy if tumor is pMMR/MSS or as subsequent therapy if not previously given
    ReferenceRegimen / finding citedNotes
    Hurwitz H et al. (Bevacizumab + irinotecan/5-FU/leucovorin)
    Supports bevacizumab combined with irinotecan and fluorouracil/leucovorin in metastatic colorectal cancer (clinical trial evidence)

    Billing, Code Lists, and Unit Limits

    HCPCS unitsmixed
    HCPCS unitsMax billable units specified per indication groups (see policy)
    HCPCS CodesHCPCS
    J9035Injection, bevacizumab, 10 mg; 1 billable unit = 10 mg
    Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg; 1 billable unit = 10 mg
    Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg; 1 billable unit = 10 mg
    Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg; 1 billable unit = 10 mg
    Q5129Injection, bevacizumab-adcd, (vegzelma), biosimilar, 10 mg; 1 billable unit = 10 mg
    Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg; 1 billable unit = 10 mg (Effective 01/01/2026)
    J9999Not otherwise classified, antineoplastic drugs (Avzivi and Jobevne only) (Discontinue use on 01/01/2026 for Jobevne only)
    NDCsNDC
    50242-0060-xxAvastin single-dose vial, 100 mg/4 mL solution for injection
    50242-0061-xxAvastin single-dose vial, 400 mg/16 mL solution for injection
    55513-0206-xxMvasi single-dose vial, 100 mg/4 mL solution for injection
    55513-0207-xxMvasi single-dose vial, 400 mg/16 mL solution for injection
    00069-0315-xxZirabev single-dose vial, 100 mg/4 mL solution for injection
    00069-0342-xxZirabev single-dose vial, 400 mg/16 mL solution for injection
    70121-1754-xxAlymsys single-dose vial, 100 mg/4 mL solution for injection
    70121-1755-xxAlymsys single-dose vial, 400 mg/16 mL solution for injection
    72606-0011-xxVegzelma single-dose vial, 100 mg/4 mL solution for injection
    72606-0012-xxVegzelma single-dose vial, 400 mg/16 mL solution for injection
    1–10 of 14
    1/2
    Covered ICD-10 Diagnosis CodesICD-10Covered
    C17.0Malignant neoplasm duodenum
    C17.1Malignant neoplasm jejunum
    C17.2Malignant neoplasm ileum
    C17.3Meckel's diverticulum, malignant
    C17.8Malignant neoplasm of overlapping sites of small intestines
    C17.9Malignant neoplasm of small intestine, unspecified
    C18.0Malignant neoplasm of cecum
    C18.1Malignant neoplasm of appendix
    C18.2Malignant neoplasm of ascending colon
    C18.3Malignant neoplasm of hepatic flexure
    1–10 of 80
    1/8
    Covered ICD-10 Diagnosis Codes (Appendix 1)ICD-10Covered
    C45.9Mesothelioma, unspecified
    C48.0Malignant neoplasm of retroperitoneum
    C48.1Malignant neoplasm of specified parts of peritoneum
    C48.2Malignant neoplasm of peritoneum, unspecified
    C48.8Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
    C49.0Malignant neoplasm of connective and soft tissue of head, face and neck
    C49.10Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
    C49.11Malignant neoplasm of connective and soft tissue of right upper limb including shoulder
    C49.12Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
    C49.20Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
    1–10 of 62
    1/7
    Max billable units per indication group
    Appendiceal / Small bowel / Ampullary180 HCPCS units per 42 days
    NSCLC / Cervical / HCC / Vaginal / Vulvar / Endometrial / Mesotheliomas170 HCPCS units per 21 days
    CRC / CNS / RCC / Respiratory Papillomatosis / All other indications360 HCPCS units per 42 days
    Dose ranges
    Lower-range dosing5 mg/kg IV every 2 weeks (also used as 7.5 mg/kg IV every 3 weeks for some indications)
    Typical maintenance/standard dosing10 mg/kg IV every 2 weeks or 7.5–15 mg/kg IV every 3 weeks depending on indication
    Highest indicated dose15 mg/kg IV every 3 weeks for NSCLC, cervical, HCC, vulvar, vaginal, endometrial, and mesotheliomas

    Authorization, Documentation, and Denial Risk Guidance

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required. Prior authorization is required and initial authorizations are generally valid for 6 months (except adult CNS symptom management which is valid for 12 weeks). Renewals may be requested every 6 months unless otherwise specified.

    • Initial validity: 6 months (12 weeks for adult CNS symptom management).
    • Renewal frequency: may be renewed every 6 months unless noted otherwise.
    • Biosimilar step requirement: patient must have a contraindication, intolerance, or failure to Alymsys® AND Mvasi® prior to consideration of another bevacizumab product.
    Documentation Required

    Renewal Authorization Requirements

    Renewal authorizations require documentation that the member continues to meet both the universal criteria and the indication‑specific criteria (including any concomitant therapy requirements where applicable). Renewals will not be issued if the original duration limit has been exceeded.

    • Renewal requires evidence the patient continues to meet universal and indication‑specific criteria including performance status and any required concomitant therapies.
    • Confirm duration of authorization not exceeded (see Length of Authorization).
    • Documentation must show disease response (stability or tumor decrease) unless the indication states otherwise.
    • Document absence of unacceptable toxicity (examples include GI perforation/fistula, wound healing complications, necrotizing fasciitis, hemorrhage, ATE/VTE, uncontrolled hypertension, PRES, nephrotic syndrome/proteinuria, severe infusion reactions, ovarian failure, CHF).
    Denial Risk

    Renewal Denial Triggers

    Renewal requests may be denied for lack of disease response, unacceptable toxicity, or if the allowed duration of prior authorization has been exceeded.

    • Denial triggers: no stabilization or tumor decrease as documented; evidence of unacceptable toxicity; authorization duration exceeded.
    Documentation Required

    Therapy History and Testing Documentation

    Therapy history and diagnostic testing must be documented when requesting initial or renewal authorization. Provide prior lines of therapy and relevant biomarker testing results per the indication.

    • Example: CRC — document prior FOLFOX/CapeOX within 12 months when indicated and MMR/MSI testing per NCCN.
    • Example: Ovarian — document BRCA1/2 status and homologous recombination deficiency testing when required; document prior use of bevacizumab if maintenance/continuation criteria apply.
    • For vaginal/vulvar cancer, document PDL1 (CPS) status when pembrolizumab combinations are requested (use FDA‑approved or CLIA‑compliant assay).
    Documentation Required

    Required Documentation for Renewal

    Required documentation for renewal must demonstrate the member continues to meet universal and indication‑specific criteria, includes evidence of concomitant therapies where applicable, and supports clinical benefit and tolerability of continued therapy.

    • Include clinical assessment showing disease response or stability per the indication.
    • Include records of concomitant therapies (e.g., chemotherapy, PARP inhibitor, immunotherapy) when required by the indication.
    • Include documentation of adverse events and rationale for continuing therapy if prior toxicity occurred.
    Billing Rule

    Required Diagnosis Coding

    Diagnosis coding: providers must submit an appropriate ICD‑10 diagnosis code from Appendix 1 that supports a covered indication when requesting prior authorization or submitting claims.

    • Use one of the covered ICD‑10 codes listed in Appendix 1 (e.g., C18.*, C20, C34.*, C51-55 series, etc.).
    • Submit the code that best reflects the treated primary site/indication and include supporting clinical documentation.
    Note

    Medicare vs Non‑Medicare Guidance

    Medicare vs Non‑Medicare Guidance. The preceding criteria are intended for non‑Medicare coverage determinations. Medicare Part B coverage follows CMS manuals and may be governed by National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs); compliance with applicable NCDs/LCDs/LCAs is required for Medicare claims.

    • For Medicare Part B, refer to Medicare Benefit Policy Manual (Pub. 100‑2), Chapter 15, §50 and search the CMS coverage database for applicable NCDs/LCDs/LCAs.
    • Local contractor guidance (e.g., NCD/LCA/LCD A52370; contractor examples) may apply—confirm the beneficiary’s jurisdiction and applicable documents before authorization.
    • Non‑Medicare determinations should follow the policy criteria in this document.
    Prior Authorization

    Prior Authorization: Consider

    Consideration for Prior Authorization. Per the NQTL Factor Checklist, indication and drug cost support applying prior authorization to this agent; safety/efficacy factors did not indicate PA as a priority alone. Prior authorization should be considered when the indication and cost factors apply.

    • NQTL assessment: Indication = Yes (consider PA); Cost of drug = Yes (consider PA); Safety/efficacy = No (PA not a priority solely for these factors).
    • Use clinical criteria and cost considerations when determining whether to require PA for a specific request.
    Documentation Required

    Combination and Sequencing Notes

    Combination and sequencing notes: many gynecologic and vulvovaginal indications specify bevacizumab in combination with particular chemotherapy agents or with PARP inhibitors/immunotherapy; sequencing and combination requirements are indication specific and must be followed.

    • Examples: Ovarian cancer — bevacizumab is described in combination with carboplatin + paclitaxel (or docetaxel) and may be used with olaparib or niraparib for maintenance in specific biomarker contexts.
    • Vaginal/vulvar cancers — bevacizumab may be used with paclitaxel plus cisplatin/carboplatin/topotecan or with pembrolizumab combinations when PDL1 CPS ≥1.
    • Follow indication‑specific sequencing (neoadjuvant, adjuvant, maintenance, or subsequent therapy) as specified in Section III.

    Line of Therapy and Sequencing Rules

    inv-51: mixed

    Mixed line‑of‑therapy rules across indications:

    Line examples: Indications specify first‑line, subsequent, maintenance, neoadjuvant, adjuvant, or rechallenge contexts depending on tumor type (examples include first‑line with atezolizumab for HCC; first‑line or subsequent in CRC; first‑line or subsequent in mesothelioma per criteria).

    inv-52: first-line | subsequent

    First‑line and subsequent therapy logic for various indications:

    Line of therapy examples: Bevacizumab is specified as first‑line or subsequent therapy depending on indication (e.g., first‑line or subsequent in vulvar/vaginal cancers; first‑line in combination regimens for certain ovarian settings; continuation after progression in some contexts).

    Biomarker and Molecular Testing Requirements

    PD-L1 (CPS)
    PD-L1 (CPS) requirementPD-L1 Combined Positive Score (CPS) ≥1 required when specified (e.g., cervical, vaginal cancer regimens with pembrolizumab)
    Test standardPD-L1 CPS must be determined by an FDA-approved or CLIA-compliant test
    Applies toCervical cancer and selected vaginal indications when used with pembrolizumab-containing regimens
    MMR / MSI (and TMB / POLE / POLD1)
    MMR / MSI requirementUniversal MMR/MSI testing recommended for CRC; use checkpoint inhibitors for dMMR/MSI-H or ultrahypermutated tumors
    TMB / POLE / POLD1Ultrahypermutated phenotype (e.g., TMB > 50 mut/Mb or POLE/POLD1 mutation) may indicate checkpoint inhibitor therapy
    Clinical impactdMMR/MSI-H or TMB>50 influences selection of immunotherapy instead of/bevacizumab-containing regimens as appropriate
    BRCA1/2 and homologous recombination (HR) status
    BRCA1/2 and HR status (ovarian)BRCA1/2 and homologous recombination (HR) status are referenced to guide use of bevacizumab with PARP inhibitors and certain single-agent or combination uses in ovarian/fallopian tube/primary peritoneal cancer
    BRCA mutation contextPatients with germline or somatic BRCA1/2 mutation qualify for specific combination/maintenance contexts (grade 2/3 endometrioid, high‑grade serous, clear cell, carcinosarcoma histologies)
    BRCA wild-type with HR deficiencyBRCA1/2 wild-type or unknown with HR deficiency is a separate eligibility pathway for selected histologies
    Actionable molecular markers
    Actionable molecular markers listedEGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, ERBB2 (HER2), and KRAS
    Testing recommendationComplete molecular testing (biopsy and/or plasma) for these markers is recommended to guide NSCLC therapy selection
    Treatment implicationIf a clinically actionable marker is found, initiate targeted therapy guided by the identified marker
    BRCA1/2 (additional references)
    BRCA1/2 referenced elsewhereBRCA1/2 testing and mutation status repeatedly referenced across ovarian cancer sections to determine eligibility for PARP combinations, maintenance, and single-agent contexts
    Histology-specific roleBRCA status is tied to histology-limited uses (e.g., grade 2/3 endometrioid, high-grade serous, clear cell, carcinosarcoma)
    Use casesGuides choice between bevacizumab alone, bevacizumab+chemotherapy, and bevacizumab+PARP inhibitor strategies
    PD-L1 (CPS) — additional instance
    PD-L1 CPS ≥1 (additional instance)PD-L1 CPS ≥1 is specified as a threshold for pembrolizumab-containing regimens in cervical, vaginal, and related indications
    Test requirementPD-L1 testing must be FDA-approved or CLIA-compliant
    Applies to pembrolizumab regimensThreshold used to determine eligibility for combinations that include pembrolizumab
    Mismatch repair / MSI (pMMR/MSS references)
    pMMR / MSS referenceSmall bowel adenocarcinoma: initial therapy indicated if proficient mismatch repair/microsatellite-stable (pMMR/MSS)
    Testing roleMMR/MSI status informs initial versus subsequent therapy decisions in small bowel and colorectal malignancies
    Clinical implicationpMMR/MSS favors fluoropyrimidine-based initial therapy with bevacizumab in small bowel adenocarcinoma

    Examples of Covered Combination Regimens

    Example context (tumor type)Example bevacizumab combination/regimenCoverage status
    Colorectal cancer / Appendiceal neoplasms
    Bevacizumab with fluoropyrimidine-based regimens (FOLFOX, CapeOX, FOLFIRI); continuation after progression described in trial data
    Gynecologic contextBevacizumab combination/regimenCoverage status
    Ovarian maintenance/recurrence and other gynecologic uses
    Bevacizumab with paclitaxel + carboplatin; carboplatin + paclitaxel or docetaxel; oxaliplatin + docetaxel (with exclusions); used as maintenance; combined with PARP inhibitors (olaparib or niraparib) when BRCA/HR criteria met
    Pediatric CNS indicationBevacizumab use/regimenCoverage status
    Diffuse high-grade glioma (≤21 years), medulloblastoma (3–21 years), optic pathway glioma (<18 years), NF2 vestibular schwannomas (≥6 years)
    Single-agent bevacizumab for palliation; as part of TEMR or MEMMAT regimens; in combination with standard therapies for age- and tumor-specific indications
    Small bowel adenocarcinoma contextBevacizumab combination/regimenCoverage status
    Advanced or metastatic small bowel adenocarcinoma
    Bevacizumab combined with a fluoropyrimidine-based regimen (e.g., 5-FU or capecitabine); used as initial therapy if pMMR/MSS
    Study / referenceRegimen involving bevacizumabTumor type / relevance
    Hurwitz H et al. (2004)
    Bevacizumab plus irinotecan, fluorouracil, and leucovorin
    Metastatic colorectal cancer (supports FOLFIRI + bevacizumab)

    Definitions and Clinical Terms

    Actionable biomarkers (recommended testing)
    Actionable biomarkers listEGFR, KRAS, ALK, ROS1, BRAF, NTRK1/2/3, MET, RET, NRG1, ERBB2 (HER2) — complete molecular testing recommended
    Testing modalitiesMolecular assessment via tissue biopsy and/or plasma testing recommended
    Clinical consequenceIdentify clinically actionable markers to guide targeted therapy in NSCLC and other tumor types as applicable
    Epithelial subtypes
    Epithelial subtypes enumeratedSerous, endometrioid, carcinosarcoma (MMMT of the ovary), clear cell, mucinous, and borderline epithelial (low malignant potential) tumors
    Context of useHistology subtypes inform eligibility for neoadjuvant, adjuvant, and maintenance bevacizumab use in ovarian/fallopian tube/primary peritoneal cancer
    Exclusions tied to subtypeSome regimens exclude grade 1 endometrioid carcinoma and low-grade serous carcinoma (noted for oxaliplatin/docetaxel contexts)

    Background and Clinical Context

    Bevacizumab and its listed biosimilars are monoclonal antibodies that inhibit vascular endothelial growth factor (VEGF) and are used to reduce tumor angiogenesis across multiple solid tumor types. In clinical practice and per this policy, bevacizumab is administered intravenously and is commonly given in combination with cytotoxic chemotherapy or immunotherapy regimens (e.g., fluoropyrimidine‑based regimens in colorectal and appendiceal cancers; carboplatin/paclitaxel in gynecologic cancers; atezolizumab plus bevacizumab in selected hepatocellular carcinoma regimens), and in selected settings may be used as single‑agent therapy for CNS symptomatic indications or maintenance after combination therapy. The policy also defines universal requirements (age, recent bleeding or surgical wound precautions, and biosimilar step requirements) and indication‑specific combinations, dosing ranges, and prior authorization expectations to guide appropriate use.